ATE414152T1 - Muteine von ifn-beta - Google Patents

Muteine von ifn-beta

Info

Publication number
ATE414152T1
ATE414152T1 AT95914045T AT95914045T ATE414152T1 AT E414152 T1 ATE414152 T1 AT E414152T1 AT 95914045 T AT95914045 T AT 95914045T AT 95914045 T AT95914045 T AT 95914045T AT E414152 T1 ATE414152 T1 AT E414152T1
Authority
AT
Austria
Prior art keywords
ifn
beta
muteins
those
recombinant dna
Prior art date
Application number
AT95914045T
Other languages
English (en)
Inventor
Susan E Goelz
Richard L Cate
E Pingchang Chow
R Blake Pepinsky
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE414152T1 publication Critical patent/ATE414152T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Amplifiers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT95914045T 1994-03-15 1995-03-13 Muteine von ifn-beta ATE414152T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/213,448 US5545723A (en) 1994-03-15 1994-03-15 Muteins of IFN-β

Publications (1)

Publication Number Publication Date
ATE414152T1 true ATE414152T1 (de) 2008-11-15

Family

ID=22795174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914045T ATE414152T1 (de) 1994-03-15 1995-03-13 Muteine von ifn-beta

Country Status (12)

Country Link
US (2) US5545723A (de)
EP (1) EP0750668B1 (de)
JP (2) JP3822903B2 (de)
AT (1) ATE414152T1 (de)
AU (1) AU695208B2 (de)
CA (1) CA2185352C (de)
DE (1) DE69535883D1 (de)
DK (1) DK0750668T3 (de)
FI (1) FI120356B (de)
NO (1) NO318989B1 (de)
NZ (2) NZ329970A (de)
WO (1) WO1995025170A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101042660B1 (ko) * 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
ATE300952T1 (de) * 1999-12-09 2005-08-15 Chiron Corp Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003025541A2 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
EP2305312B1 (de) 2001-10-10 2015-03-04 ratiopharm GmbH Neumodulierung und Glykokonjugation von Follitropin (FSH)
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
PL377612A1 (pl) * 2002-09-27 2006-02-06 Biogen Idec Ma Inc. Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß
AU2003277088A1 (en) * 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
EP1615945B1 (de) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006122971A2 (en) * 2005-05-19 2006-11-23 Bayer Schering Pharma Aktiengesellschaft Treatment of disease using an improved regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
EP1891224A1 (de) * 2005-05-19 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Interferon-beta-gentherapie unter verwendung eines verbesserten, regulierten expressionssystems
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
US20100196328A1 (en) * 2007-04-25 2010-08-05 Tonya Bliss ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION
EP2076533B1 (de) * 2007-05-02 2014-10-08 Ambrx, Inc. Modifizierte interferon-beta-polypeptide und ihre verwendungen
EP2207890A4 (de) * 2007-10-05 2010-12-15 Barofold Inc Hochdruckbehandlung aggregierter interferone
EP2379711B8 (de) 2008-12-23 2017-03-22 BOCO Silicon Valley, Inc. Zielpopulationen von oligodendrozyten-vorläuferzellen und verfahren zur herstellung und verwendung davon
WO2019073315A1 (en) 2017-10-09 2019-04-18 Mansour Poorebrahim ANALOGUE PEPTIDE OF INTERFERON-BETA

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2687995B2 (ja) * 1980-04-03 1997-12-08 バイオゲン インコーポレイテッド Ｄｎａ配列、組替えｄｎａ分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
EP0260350B1 (de) * 1986-09-05 1992-02-12 Cetus Oncology Corporation Oxidationsresistente Muteine von beta-Interferon, deren Herstellung und diese Muteine enthaltende Präparate
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL92124A (en) * 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
WO1993015609A1 (en) * 1992-02-05 1993-08-19 Thomas Jefferson University Interferon gene therapy for the treatment of vascular disorders

Also Published As

Publication number Publication date
WO1995025170A1 (en) 1995-09-21
AU2120295A (en) 1995-10-03
EP0750668A1 (de) 1997-01-02
EP0750668B1 (de) 2008-11-12
NZ329970A (en) 2000-01-28
NZ283217A (en) 1998-05-27
CA2185352A1 (en) 1995-09-21
FI120356B (fi) 2009-09-30
US5545723A (en) 1996-08-13
DK0750668T3 (da) 2009-03-02
NO963837D0 (no) 1996-09-13
CA2185352C (en) 2005-02-22
JPH10500563A (ja) 1998-01-20
FI963630A0 (fi) 1996-09-13
JP3822903B2 (ja) 2006-09-20
FI963630A7 (fi) 1996-09-13
DE69535883D1 (de) 2008-12-24
AU695208B2 (en) 1998-08-06
JP2006199711A (ja) 2006-08-03
NO318989B1 (no) 2005-05-30
MX9604073A (es) 1997-12-31
US6127332A (en) 2000-10-03
NO963837L (no) 1996-11-14

Similar Documents

Publication Publication Date Title
ATE414152T1 (de) Muteine von ifn-beta
DK75694A (da) Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren
NO914541L (no) Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner
RU95115239A (ru) Аналог эритропоэтина
NO961639L (no) Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav
DK0880970T3 (da) Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose
NO931141L (no) Tnf-muteiner
SE9004010D0 (sv) Viralt medel
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
WO2002074980A3 (en) Muteins of hypoxia inducible factor alpha and methods of use thereof
EP0592566A4 (de) Cysteinfreie il-6 mutanten.
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE100717T1 (de) Intralaesionale behandlung von basalzellenkarzinoma mittels rekombinanten humanen alpha-interferons.
DE59208025D1 (de) Neue thrombininhibitorische proteine aus landblutegeln
IL92495A0 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
DE68918399D1 (de) Lymphokine, DNS-Sequenzen, die diese Lymphokine kodieren, und sie enthaltende pharmazeutische Zusammensetzungen.
IT1262545B (it) Sistema di espressione per linee cellulari eucariotiche
ATE386803T1 (de) Intrazelluläre glukocortikoid-induzierte leucin- zipper modulatoren von mechanismen des apoptotischen zelltodes
Yamaguchi et al. A procedure for the purification of ferritin using Matrex Red A

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties